RELAPSED/REFRACTORY B-CELL MALIGNANCIES
Clinical trials for RELAPSED/REFRACTORY B-CELL MALIGNANCIES explained in plain language.
Never miss a new study
Get alerted when new RELAPSED/REFRACTORY B-CELL MALIGNANCIES trials appear
Sign up with your email to follow new studies for RELAPSED/REFRACTORY B-CELL MALIGNANCIES, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New cell therapy takes aim at Hard-to-Treat blood cancers
Disease control Not yet recruitingThis early-stage study tests a new treatment called LVIVO-TaVec122 in 48 adults with B-cell blood cancers that have come back or not responded to standard therapy. The main goals are to check safety, find the right dose, and measure how long the treatment lasts in the body. It is…
Matched conditions: RELAPSED/REFRACTORY B-CELL MALIGNANCIES
Phase: PHASE1 • Sponsor: The First Affiliated Hospital with Nanjing Medical University • Aim: Disease control
Last updated Jun 27, 2026 13:03 UTC
-
New injection aims to control tough blood cancers in early trial
Disease control Not yet recruitingThis early-phase study tests a new drug called SYS6055 in 86 adults whose B-cell cancers (like certain leukemias or lymphomas) have come back or not responded to standard treatments. The main goals are to check safety, find the best dose, and see if it helps shrink tumors or cont…
Matched conditions: RELAPSED/REFRACTORY B-CELL MALIGNANCIES
Phase: PHASE1 • Sponsor: Institute of Hematology & Blood Diseases Hospital, China • Aim: Disease control
Last updated Jun 27, 2026 12:07 UTC